{
    "2019-06-17": [
        [
            {
                "time": "2023-10-05",
                "original_text": "J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study",
                "features": {
                    "keywords": [
                        "JNJ",
                        "Tremfya",
                        "Goal",
                        "Psoriatic Arthritis",
                        "Study"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz",
                "features": {
                    "keywords": [
                        "Novartis",
                        "NVS",
                        "Promising Data",
                        "Tasigna",
                        "Hyrimoz"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}